GRK4 Polymorphisms Blood Pressure Response to Candesartan
试验速览
- 阶段
- 4 期
- 入组人数
- 500
- 试验地点
- 1
- 主要终点
- The subjects with GRK4 varirants may exert different response during 4 weeks of treatment with candesartan in patients with essential hypertension
研究概览
简要总结
The purpose of this study is to investigate the association between GRK4 polymorphisms and essential hypertension in southwestern Han Chinese and test whether these polymorphisms were associated with the changes in blood pressure in patients with essential hypertension treated with angiotensin II Type antagonist candesartan.
详细描述
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥ 90 mmHg.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- Single (Participant)
入排标准
- 年龄范围
- 30 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •men and women with mild to moderate essential hypertension in southwestern Han Chinese
排除标准
- •subjects unwilling to participate or subjects did not have all measurement required,
- •subjects who were on medications, which affect blood pressure or
- •whose DNA failed to amplify and 8 with errors in Mendelian segregation
研究组 & 干预措施
candesartan
All antihypertensive agents were withdrawn before the start of a 4-6 week, single-blind, after which the patients received candesartan 10 mg or 20 mg once daily as monotherapy in a single-blind fashion. The doses were doubled after 1 weeks if DBP was ≥90 mmHg.
干预措施: Candesartan (Drug)
结局指标
主要结局
The subjects with GRK4 varirants may exert different response during 4 weeks of treatment with candesartan in patients with essential hypertension
时间窗: two years
次要结局
未报告次要终点
研究者
Yu Changqing
Department of Cardiovascular Diseases; Institute of Cardiovascular Diseases; Daping Hospital;
Third Military Medical University